Business
GE HealthCare Completes Acquisition of Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan
GE HealthCare has completed its acquisition of Sumitomo Chemical’s 50% stake in Nihon Medi-Physics (NMP), giving it full ownership. As part of GE HealthCare,
About this update from Ge Healthcare Technologies Inc.
[{"type":"text","content":"\n\nGE HealthCare has completed its acquisition of Sumitomo Chemical’s 50% stake in Nihon Medi-Physics (NMP), giving it full ownership.\n\n\nAs part of GE HealthCare, NMP, already a leading radiopharmaceutical company in Japan, is positioned to enhance patient access to next-generation radiopharmaceuticals that enable detection and diagnosis of disease\n\n\nKevin O’Neill, President & CEO of GE HealthCare’s Pharmaceutical Diagnostics segment, will also become President of NMP.\n\n\n CHICAGO--(BUSINESS WIRE)--\nGE HealthCare Technologies Inc. (GE HealthCare or the Company) (Nasdaq: GEHC) has completed its acquisition of the remaining 50% stake in Nihon Medi-Physics Co., Ltd (NMP), from Sumitomo Chemical, giving it full ownership. As part of GE HealthCare, NMP can further build on its expertise in developing and manufacturing proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging procedures to detect and diagnose disease.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250330506353/en/Nihon Medi-Physics headquarters and radiopharmaceutical imaging agents about to go through labelling and packing process.\nKevin O’Neill, President & CEO of GE HealthCare’s Pharmaceutical Diagnostics (PDx) segment, who will also become President of NMP, said: “We are delighted to welcome Nihon Medi-Physics to GE HealthCare, increasing our existing footprint and offering in Japan, where our contrast media and medical devices are used every day to enable imaging procedures across the country. Japan is on a path to becoming a leader in the $7 billion molecular imaging global market1 and a center of excellence for Asian markets. As part of GE HealthCare, NMP will play a key role in that journey, including bringing its deep expertise and scale to global innovators looking to bring next-generation radiopharmaceuticals to the Japan market and beyond.”\n\nNMP’s product portfolio includes GE HealthCare radiopharmaceuticals used to enable molecular imaging across neurology, cardiology and oncology procedures. NMP, headquartered in Tokyo, was formed in 1973 and generated revenues of 28.2B JPY (~$183M) in 2023. GE HealthCare acquired Amersham plc in 2004, and subsequently held a 50% stake in NM...